Literature DB >> 27393547

Comparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.

S Foongladda1, S Banu2, S Pholwat3, J Gratz3, S O-Thong1, N Nakkerd1, R Chinli1, S S Ferdous2, S M M Rahman2, A Rahman2, S Ahmed2, S Heysell3, M Sariko4, G Kibiki4, E Houpt3.   

Abstract

BACKGROUND: Although phenotypic drug susceptibility testing (DST) is endorsed as the standard for second-line drug testing of Mycobacterium tuberculosis, it is slow and laborious.
METHODS: We evaluated the accuracy of two faster, easier methodologies that provide results for multiple drugs: a genotypic TaqMan(®) Array Card (TAC) and the Sensititre(®) MYCOTB(TM) plate. Both methods were tested at three central laboratories in Bangladesh, Tanzania, and Thailand with 212 multidrug-resistant tuberculosis (MDR-TB) isolates and compared with the laboratories' phenotypic method in use.
RESULTS: The overall accuracy for ethambutol, streptomycin, amikacin, kanamycin, ofloxacin, and moxifloxacin vs. the phenotypic standard was 87% for TAC (range 70-99) and 88% for the MYCOTB plate (range 76-98). To adjudicate discordances, we re-defined the standard as the consensus of the three methods, against which the TAC and MYCOTB plate yielded 94-95% accuracy, while the phenotypic result yielded 93%. Some isolates with genotypic mutations and high minimum inhibitory concentration (MIC) were phenotypically susceptible, and some isolates without mutations and low MIC were phenotypically resistant, questioning the phenotypic standard.
CONCLUSIONS: In our view, the TAC, the MYCOTB plate, and the conventional phenotypic method have similar performance for second-line drugs; however, the former methods offer speed, throughput, and quantitative DST information.

Entities:  

Mesh:

Year:  2016        PMID: 27393547      PMCID: PMC4937751          DOI: 10.5588/ijtld.15.0896

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  18 in total

1.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

2.  Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.

Authors:  Sayera Banu; S M Mazidur Rahman; M Siddiqur Rahman Khan; Sara Sabrina Ferdous; Shahriar Ahmed; Jean Gratz; Suzanne Stroup; Suporn Pholwat; Scott K Heysell; Eric R Houpt
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

3.  Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Sophia B Georghiou; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Diagn Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 2.803

4.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

5.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Authors:  D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

6.  Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Tuberculosis (Edinb)       Date:  2014-12-03       Impact factor: 3.131

7.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Authors:  Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

8.  Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs.

Authors:  Jongseok Lee; Derek T Armstrong; Willy Ssengooba; Jeong-Ae Park; Yeuni Yu; Francis Mumbowa; Carolyn Namaganda; Gerald Mboowa; Germine Nakayita; Sandra Armakovitch; Gina Chien; Sang-Nae Cho; Laura E Via; Clifton E Barry; Jerrold J Ellner; David Alland; Susan E Dorman; Moses L Joloba
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

9.  Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes.

Authors:  Suporn Pholwat; Jie Liu; Suzanne Stroup; Jean Gratz; Sayera Banu; S M Mazidur Rahman; Sara Sabrina Ferdous; Suporn Foongladda; Duangjai Boonlert; Oleg Ogarkov; Svetlana Zhdanova; Gibson Kibiki; Scott Heysell; Eric Houpt
Journal:  MBio       Date:  2015-02-24       Impact factor: 7.867

10.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

View more
  12 in total

Review 1.  Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

Authors:  Samantha Pillay; Karen R Steingart; Geraint R Davies; Marty Chaplin; Margaretha De Vos; Samuel G Schumacher; Rob Warren; Grant Theron
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

2.  Simultaneous detection of multiple pathogens with the TaqMan Array Card.

Authors:  Rachael Lappan; Thanavit Jirapanjawat; Deborah A Williamson; Sigrid Lange; Steven L Chown; Chris Greening
Journal:  MethodsX       Date:  2022-04-20

3.  The Malaria TaqMan Array Card Includes 87 Assays for Plasmodium falciparum Drug Resistance, Identification of Species, and Genotyping in a Single Reaction.

Authors:  Suporn Pholwat; Jie Liu; Suzanne Stroup; Shevin T Jacob; Patrick Banura; Christopher C Moore; Fang Huang; Miriam K Laufer; Eric Houpt; Jennifer L Guler
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.

Authors:  Darwin J Operario; Alexander F Koeppel; Stephen D Turner; Yongde Bao; Suporn Pholwat; Sayera Banu; Suporn Foongladda; Stellah Mpagama; Jean Gratz; Oleg Ogarkov; Svetlana Zhadova; Scott K Heysell; Eric R Houpt
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

5.  Performance of TaqMan array card to detect TB drug resistance on direct specimens.

Authors:  Sayera Banu; Suporn Pholwat; Suporn Foongladda; Rattapha Chinli; Duangjai Boonlert; Sara Sabrina Ferdous; S M Mazidur Rahman; Arfatur Rahman; Shahriar Ahmed; Eric R Houpt
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

6.  Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.

Authors:  Hui Xia; Yang Zheng; Bing Zhao; Susan van den Hof; Frank Cobelens; YanLin Zhao
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

7.  Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.

Authors:  Carolien Ruesen; Anca Lelia Riza; Adriana Florescu; Lidya Chaidir; Cornelia Editoiu; Nicole Aalders; Dragos Nicolosu; Victor Grecu; Mihai Ioana; Reinout van Crevel; Jakko van Ingen
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

8.  Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Authors:  Mohammad H Al-Shaer; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; J Peter Cegielski; Russell R Kempker; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

9.  Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.

Authors:  Saumu Pazia Juma; Athanasia Maro; Suporn Pholwat; Stellah G Mpagama; Jean Gratz; Alphonse Liyoyo; Eric R Houpt; Gibson S Kibiki; Blandina T Mmbaga; Scott K Heysell
Journal:  BMC Infect Dis       Date:  2019-02-07       Impact factor: 3.090

Review 10.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.